ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts from the company’s diverse portfolio of industry-leading innovative HIV treatment and prevention options alongside next-generation pipeline advancements at the Conference on Retroviruses and Opportunistic Infections (CROI 2023)being held in Seattle, Washington from 19 – 22 February 2023.

Additional information to the following link: https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-first-head-to-head-data-for-long-acting-hiv-treatment-cabenuva-against-daily-oral-biktarvy-at-croi-2023/